|
1 |
Intermediate-dose TBI/fludarabine conditioning for allogeneic hematopoietic cell transplantation in patients with peripheral T-cell lymphoma
Enthalten in Bone marrow transplantation 13.2.2025: 1-6
|
|
|
2 |
Allogeneic hematopoietic cell transplantation for myelofibrosis aged 70 years or older: a study from the German Registry for Stem Cell Transplantation
Gagelmann, Nico. - Freiburg : Universität, 2024
|
|
|
|
3 |
Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients
Schmälter, Ann-Kristin. - Freiburg : Universität, 2024
|
|
|
|
4 |
How risky is a second allogeneic stem cell transplantation?
Penack, Olaf. - Freiburg : Universität, 2024
|
|
|
|
5 |
Management of patients undergoing CAR-T cell therapy in Germany
Penack, Olaf. - Augsburg : Universität Augsburg, 2024
|
|
|
|
6 |
Outcomes of haploidentical transplants with PT-CY versus 10/10 MUD transplants with ATG in Germany
Arslan, Aysenur. - Freiburg : Universität, 2024
|
|
|
|
7 |
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas
Liebers, Nora. - Würzburg : Universität Würzburg, 2024
|
|
|
|
8 |
Third-generation CD19.CAR-T cell-containing combination therapy in Scl70+ systemic sclerosis
Merkt, Wolfgang. - Freiburg : Universität, 2024
|
|
|
|
9 |
Barriers and Facilitators in Continuous Medical Education Related to Allogeneic Stem Cell Transplantation: A Qualitative Study of Physicians
Enthalten in Oncology research and treatment Bd. 47, 2024, Nr. 4: 136-144. 9 S.
|
|
|
|
10 |
Management of Patients Undergoing CAR-T Cell Therapy in Germany
Enthalten in Oncology research and treatment Bd. 47, 2024, Nr. 3: 65-75. 10 S.
|
|
Administration
